Ethical Considerations for Increased Transparency and Reproducibility in the Retrospective Analysis of Health Care Data
- PMID: 30222403
- DOI: 10.1177/2168479015578155
Ethical Considerations for Increased Transparency and Reproducibility in the Retrospective Analysis of Health Care Data
Abstract
In the field of health care, researchers and decision makers are increasingly turning toward retrospective observational studies of administrative claims and electronic health record databases to improve outcomes for patients. For many important questions, randomized studies have not been conducted, and even when they have been, such studies often inadequately reflect the realities of patients' lives or care. However, use of retrospective studies not only increases methodological complexity but also requires more subjectivity for those attempting to perform statistical analysis. The hurdles for establishing the reproducibility of such research to ensure accuracy and generalizability are therefore also higher, as are the requirements for transparency to limit the impact of bias. The ethical statistical practitioner will therefore need to take additional steps to enable results to be interpreted and acted upon with confidence. These include increased transparency regarding the impact of database selection, database quality, database content, and design decisions on the robustness of statistical conclusions. A number of approaches to increase the reproducibility of retrospective health care research are also presented, along with some discussion regarding responsibilities of data owners, statistical practitioners, publishers, and users of results.
Keywords: comparative effectiveness; ethics; observational; retrospective; statistics.
Similar articles
-
The project data sphere initiative: accelerating cancer research by sharing data.Oncologist. 2015 May;20(5):464-e20. doi: 10.1634/theoncologist.2014-0431. Epub 2015 Apr 15. Oncologist. 2015. PMID: 25876994 Free PMC article.
-
Procedures and methods of benefit assessments for medicines in Germany.Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5. Eur J Health Econ. 2008. PMID: 18987905
-
[Procedures and methods of benefit assessments for medicines in Germany].Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. Dtsch Med Wochenschr. 2008. PMID: 19034813 German.
-
Issues in data monitoring and interim analysis of trials.Health Technol Assess. 2005 Mar;9(7):1-238, iii-iv. doi: 10.3310/hta9070. Health Technol Assess. 2005. PMID: 15763038 Review.
-
Generalisability in economic evaluation studies in healthcare: a review and case studies.Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. doi: 10.3310/hta8490. Health Technol Assess. 2004. PMID: 15544708 Review.
Cited by
-
Replicating a COVID-19 study in a national England database to assess the generalisability of research with regional electronic health record data.BMJ Open. 2025 Apr 23;15(4):e093080. doi: 10.1136/bmjopen-2024-093080. BMJ Open. 2025. PMID: 40268487 Free PMC article.
-
A machine learning framework to adjust for learning effects in medical device safety evaluation.J Am Med Inform Assoc. 2025 Jan 1;32(1):206-217. doi: 10.1093/jamia/ocae273. J Am Med Inform Assoc. 2025. PMID: 39471493
-
Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium.iScience. 2023 Mar 15;26(4):106411. doi: 10.1016/j.isci.2023.106411. eCollection 2023 Apr 21. iScience. 2023. PMID: 37091238 Free PMC article.
-
Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19.Sci Rep. 2023 Sep 28;13(1):16292. doi: 10.1038/s41598-023-43412-3. Sci Rep. 2023. PMID: 37770596 Free PMC article. Clinical Trial.
-
Adherence to screening and management guidelines of maternal Group B Streptococcus colonization in pregnancy.J Adv Nurs. 2022 Oct;78(10):3247-3260. doi: 10.1111/jan.15249. Epub 2022 Apr 15. J Adv Nurs. 2022. PMID: 35429021 Free PMC article.